Daina B Esposito1, Stephan Lanes1, Macarius Donneyong1, Crystal N Holick1, Joseph A Lasky2, David Lederer3, Steven D Nathan4, Sean O'Quinn5, Joseph Parker6, Trung N Tran7. 1. 1 Safety and Epidemiology, HealthCore, Inc, Andover, Massachusetts. 2. 2 Pulmonary and Critical Care, Tulane University School of Medicine, New Orleans, Louisiana. 3. 3 Division of Pulmonary, Allergy and Critical Care Medicine, Columbia University Medical Center, New York, New York. 4. 4 Lung Transplant and Advanced Lung Disease Programs, Inova Fairfax Hospital, Falls Church, Virginia. 5. 5 Patient-Reported Outcomes and. 6. 6 Clinical Development, MedImmune, Gaithersburg, Maryland. 7. 7 Observational Research Center, AstraZeneca, Gaithersburg, Maryland; and.
Abstract
RATIONALE: Estimates of idiopathic pulmonary fibrosis (IPF) incidence and prevalence from electronic databases without case validation may be inaccurate. OBJECTIVES: Develop claims algorithms to identify IPF and assess their positive predictive value (PPV) to estimate incidence and prevalence in the United States. METHODS: We developed three algorithms to identify IPF cases in the HealthCore Integrated Research Database. Sensitive and specific algorithms were developed based on literature review and consultation with clinical experts. PPVs were assessed using medical records. A third algorithm used logistic regression modeling to generate an IPF score and was validated using a separate set of medical records. We estimated incidence and prevalence of IPF using the sensitive algorithm corrected for the PPV. MEASUREMENTS AND MAIN RESULTS: We identified 4,598 patients using the sensitive algorithm and 2,052 patients using the specific algorithm. After medical record review, the PPVs of these algorithms using the treating clinician's diagnosis were 44.4 and 61.7%, respectively. For the IPF score, the PPV was 76.2%. Using the clinical adjudicator's diagnosis, the PPVs were 54 and 57.6%, respectively, and for the IPF score, the PPV was 83.3%. The incidence and period prevalences of IPF, corrected for the PPV, were 14.6 per 100,000 person-years and 58.7 per 100,000 persons, respectively. CONCLUSIONS: Sensitive algorithms without correction for false positive errors overestimated incidence and prevalence of IPF. An IPF score offered the greatest PPV, but it requires further validation.
RATIONALE: Estimates of idiopathic pulmonary fibrosis (IPF) incidence and prevalence from electronic databases without case validation may be inaccurate. OBJECTIVES: Develop claims algorithms to identify IPF and assess their positive predictive value (PPV) to estimate incidence and prevalence in the United States. METHODS: We developed three algorithms to identify IPF cases in the HealthCore Integrated Research Database. Sensitive and specific algorithms were developed based on literature review and consultation with clinical experts. PPVs were assessed using medical records. A third algorithm used logistic regression modeling to generate an IPF score and was validated using a separate set of medical records. We estimated incidence and prevalence of IPF using the sensitive algorithm corrected for the PPV. MEASUREMENTS AND MAIN RESULTS: We identified 4,598 patients using the sensitive algorithm and 2,052 patients using the specific algorithm. After medical record review, the PPVs of these algorithms using the treating clinician's diagnosis were 44.4 and 61.7%, respectively. For the IPF score, the PPV was 76.2%. Using the clinical adjudicator's diagnosis, the PPVs were 54 and 57.6%, respectively, and for the IPF score, the PPV was 83.3%. The incidence and period prevalences of IPF, corrected for the PPV, were 14.6 per 100,000 person-years and 58.7 per 100,000 persons, respectively. CONCLUSIONS: Sensitive algorithms without correction for false positive errors overestimated incidence and prevalence of IPF. An IPF score offered the greatest PPV, but it requires further validation.
Authors: Bryant R England; Punyasha Roul; Tina D Mahajan; Namrata Singh; Fang Yu; Harlan Sayles; Grant W Cannon; Brian C Sauer; Joshua F Baker; Jeffrey R Curtis; Ted R Mikuls Journal: Arthritis Care Res (Hoboken) Date: 2020-10 Impact factor: 4.794
Authors: Marco A Alba; Luis Felipe Flores-Suárez; Ashley G Henderson; Hong Xiao; Peiqi Hu; Patrick H Nachman; Ronald J Falk; J Charles Jennette Journal: Autoimmun Rev Date: 2017-05-04 Impact factor: 9.754
Authors: Brett Ley; Thomas Urbania; Gail Husson; Eric Vittinghoff; David R Brush; Mark D Eisner; Carlos Iribarren; Harold R Collard Journal: Ann Am Thorac Soc Date: 2017-06
Authors: Stacey-Ann Whittaker Brown; Maria Padilla; Grace Mhango; Emanuela Taioli; Charles Powell; Juan Wisnivesky Journal: Ann Am Thorac Soc Date: 2019-08
Authors: Erica Farrand; Carlos Iribarren; Eric Vittinghoff; Tory Levine-Hall; Brett Ley; George Minowada; Harold R Collard Journal: Chest Date: 2020-07-24 Impact factor: 9.410
Authors: Bhavika Kaul; Joyce S Lee; Ning Zhang; Eric Vittinghoff; Kathleen Sarmiento; Harold R Collard; Mary A Whooley Journal: Ann Am Thorac Soc Date: 2022-02
Authors: Toby M Maher; Elisabeth Bendstrup; Louis Dron; Jonathan Langley; Gerald Smith; Javaria Mona Khalid; Haridarshan Patel; Michael Kreuter Journal: Respir Res Date: 2021-07-07